Avoiding Absolute Quantification Trap: A Novel Predictive Signature of Clinical Benefit to Anti-PD-1 Immunotherapy in Non-Small Cell Lung Cancer

Código QR

Avoiding Absolute Quantification Trap: A Novel Predictive Signature of Clinical Benefit to Anti-PD-1 Immunotherapy in Non-Small Cell Lung Cancer

Immunotherapy has been focused on by many oncologists and researchers. While, due to technical biases of absolute quantification, few traditional biomarkers for anti-PD-1 immunotherapy have been applied in regular clinical practice of non-small cell lung cancer (NSCLC). Therefore, there is an urgent...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Chengming Liu, Sihui Wang, Sufei Zheng, Fei Xu, Zheng Cao, Xiaoli Feng, Yan Wang, Qi Xue, Nan Sun, Jie He
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	NSCLC immune checkpoint inhibitors clinical benefit prognosis BRGPI Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/33bd7fb95ba8489280d6f58b400ea218
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Immunotherapy in the First-Line Treatment of NSCLC: Current Status and Future Directions in China
por: Anwen Xiong, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio
por: Alberto Bongiovanni, et al.
Publicado: (2021)

Predictable Roles of Peripheral IgM Memory B Cells for the Responses to Anti-PD-1 Monotherapy Against Advanced Non-Small Cell Lung Cancer
por: Liliang Xia, et al.
Publicado: (2021)

Neoadjuvant immunotherapy combined with chemotherapy for locally advanced squamous cell lung carcinoma: A case report and literature review
por: Zheng Yuan, et al.
Publicado: (2021)

Identification of a Pyroptosis-Related Gene Signature for Predicting Overall Survival and Response to Immunotherapy in Hepatocellular Carcinoma
por: Susu Zheng, et al.
Publicado: (2021)

Hepatoid adenocarcinoma of the lung: An analysis of the Surveillance, Epidemiology, and End Results (SEER) database
por: Lei Lei, et al.
Publicado: (2021)

RNA N6‐methyladenosine modification in the lethal teamwork of cancer stem cells and the tumor immune microenvironment: Current landscape and therapeutic potential
por: Zhihui Zhang, et al.
Publicado: (2021)

Role of Rho Guanine Nucleotide Exchange Factors in Non-Small Cell Lung Cancer
por: Rui-Jie Zeng, et al.
Publicado: (2021)

Small cell lung cancer transformation during antitumor therapies: A systematic review
por: Chai Xing, et al.
Publicado: (2021)

Cancer Vaccines and Immunotherapy for Tumor Prevention and Treatment
por: Jagmohan Singh, et al.
Publicado: (2021)

Nanosonosensitizer-Augmented Sonodynamic Therapy Combined with Checkpoint Blockade for Cancer Immunotherapy
por: Lin X, et al.
Publicado: (2021)

Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma
por: Rui Xing, et al.
Publicado: (2021)

The Half-Life-Extended IL21 can Be Combined With Multiple Checkpoint Inhibitors for Tumor Immunotherapy
por: Shaoxian Wu, et al.
Publicado: (2021)

Immunotherapy for triple-negative breast cancer: A molecular insight into the microenvironment, treatment, and resistance
por: Xupeng Bai, et al.
Publicado: (2021)

Keratinocyte differentiation antigen-specific T cells in immune checkpoint inhibitor-treated NSCLC patients are associated with improved survival
por: Fiamma Berner, et al.
Publicado: (2021)

Blocking hsa_circ_0074027 suppressed non-small cell lung cancer chemoresistance via the miR-379-5p/IGF1 axis
por: Shizhen Zheng, et al.
Publicado: (2021)

Multi-Omics Analysis of Novel Signature for Immunotherapy Response and Tumor Microenvironment Regulation Patterns in Urothelial Cancer
por: Guangdi Chu, et al.
Publicado: (2021)

Prognostic value of microRNA-4521 in non-small cell lung cancer and its regulatory effect on tumor progression
por: Sun Butong, et al.
Publicado: (2021)

Immunotherapy in Medulloblastoma: Current State of Research, Challenges, and Future Perspectives
por: Marije J. Voskamp, et al.
Publicado: (2021)

p53-Independent checkpoint controls in a plant cell model
por: PELAYO,HELVIA R, et al.
Publicado: (2003)

A review on the evolution of immunotherapy in bladder carcinoma
por: Milena Gulinac, et al.
Publicado: (2020)

Anti-PD1 Therapy Plus Whole-Brain Radiation Therapy May Prolong PFS in Selected Non–Small Cell Lung Cancer Patients with Brain Metastases: A Retrospective Study
por: Khan M, et al.
Publicado: (2021)

Pan-Cancer Analysis Reveals Alternative Splicing Characteristics Associated With Immune-Related Adverse Events Elicited by Checkpoint Immunotherapy
por: Xiujing He, et al.
Publicado: (2021)

CANCER IMMUNOTHERAPY BASED ON THE BLOCKADE OF IMMUNE CHECKPOINTS
por: A. V. Bogolyubova, et al.
Publicado: (2015)

Nanobubbles Containing sPD-1 and Ce6 Mediate Combination Immunotherapy and Suppress Hepatocellular Carcinoma in Mice
por: Tan Y, et al.
Publicado: (2021)

Rheumatic Manifestations and Diseases From Immune Checkpoint Inhibitors in Cancer Immunotherapy
por: Pan Shen, et al.
Publicado: (2021)

Combined treatment of non‐small cell lung cancer using radiotherapy and immunotherapy: challenges and updates
por: Shijie Shang, et al.
Publicado: (2021)

circAGFG1 sponges miR-28-5p to promote non-small-cell lung cancer progression through modulating HIF-1α level
por: Ma Xiaoan, et al.
Publicado: (2021)

Endostar (rh‐endostatin) improves efficacy of concurrent chemoradiotherapy for locally advanced non‐small cell lung cancer: A systematic review and meta‐analysis
por: Meng Yuan, et al.
Publicado: (2021)

Mediastinoscopy: safety and utility Cervical mediastinoscopy: assessing mediastinal lymphadenopathy at Manmohan Cardio-thoracic Vascular and Transplant center
por: Bibhusal Thapa
Publicado: (2016)

The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis
por: He Ba, et al.
Publicado: (2021)

Progress in the Application of Immune Checkpoint Inhibitor-Based Immunotherapy for Targeting Different Types of Colorectal Cancer
por: Rui He, et al.
Publicado: (2021)

Comprehensive Analysis of Subtype-Specific Molecular Characteristics of Colon Cancer: Specific Genes, Driver Genes, Signaling Pathways, and Immunotherapy Responses
por: Fangjie Hu, et al.
Publicado: (2021)

Identification of circRNA_001846 as putative non–small cell lung cancer biomarker
por: Fan Yang, et al.
Publicado: (2021)

Crossed Pathways for Radiation-Induced and Immunotherapy-Related Lung Injury
por: Zengfu Zhang, et al.
Publicado: (2021)

Combination Cancer Immunotherapy of Nanoparticle-Based Immunogenic Cell Death Inducers and Immune Checkpoint Inhibitors
por: Qi J, et al.
Publicado: (2021)

Targeting Tumor-Associated Macrophages in Cancer Immunotherapy
por: Amy J. Petty, et al.
Publicado: (2021)

Hypoxic Characteristic Genes Predict Response to Immunotherapy for Urothelial Carcinoma
por: Shuo Hong, et al.
Publicado: (2021)

Editorial: Immunotherapy as an Evolving Approach for the Treatment of Breast Cancer
por: Mai F. Tolba, et al.
Publicado: (2021)

Polymyalgia rheumatica with normal inflammatory indices at the time of diagnosis: can we just move a step forward?
por: Ciro Manzo, et al.
Publicado: (2020)